Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 325Pancreatic Neoplasms 189Carcinoma, Hepatocellular 119Stomach Neoplasms 116Colonic Neoplasms 87Esophageal Neoplasms 85Carcinoma, Non-Small-Cell Lung 84Breast Neoplasms 80Rectal Neoplasms 78Ovarian Neoplasms 65Neoplasm Metastasis 61Lung Neoplasms 61Neoplasms 57Cholangiocarcinoma 55Liver Neoplasms 47Melanoma 46Gastrointestinal Neoplasms 46Prostatic Neoplasms 43Biliary Tract Neoplasms 37Endometrial Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Sarcoma 32Carcinoma, Renal Cell 30Esophageal Squamous Cell Carcinoma 28Uterine Cervical Neoplasms 27Head and Neck Neoplasms 25Adenocarcinoma Of Esophagus 24Urinary Bladder Neoplasms 23Small Cell Lung Carcinoma 20Triple Negative Breast Neoplasms 17

Interventions

Taxes 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × Gastrointestinal × 30 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡